These two are not alternatives, and any page presenting them as a choice has confused a menu with a category. Sermorelin is a 29-amino-acid peptide that tells your pituitary to release growth hormone. NAD⁺ is a coenzyme your cells use to move electrons through metabolism. One is a signal sent to a gland; the other is a working part inside every cell. Nothing about picking one tells you anything about the other.
You are being asked to compare them because they are sold together. Telehealth services that ship compounded injections list sermorelin, ipamorelin, BPC-157, glutathione and NAD⁺ on one page, under one intake, on one subscription — and a shared checkout reads to a buyer as a shared family of products. It is not one. NAD⁺ is not even a peptide, which is a sentence worth its own page because so many sellers get it wrong in their own marketing.
What sermorelin has actually been shown to do
Quite a lot, in a population that is almost certainly not you.
Sermorelin is the shortest synthetic peptide with the full biological activity of growth hormone-releasing hormone, and given intravenously or subcutaneously it specifically stimulates growth hormone secretion from the anterior pituitary. A single 1 µg/kg intravenous dose is a rapid and relatively specific test for diagnosing growth hormone deficiency, with fewer false positive responses in children without the deficiency than other provocative tests [1].
As a treatment, the evidence is about growth in children. In a multicenter study, 110 previously untreated prepubertal growth-hormone-deficient children (n = 110) received 30 µg/kg a day subcutaneously at bedtime for up to a year. Mean height velocity rose from 4.1 ± 0.9 cm a year at baseline to 8.0 ± 1.5 at six months and 7.2 ± 1.3 at twelve; 74% were considered good responders at six months, and no adverse changes in general biochemical or hormonal analyses were noted [2].
The review covering that literature adds the comparison the marketing never does: increases in height velocity on subcutaneous sermorelin were less than in children given once-daily somatropin — growth hormone itself — at the same microgram-per-kilogram dose. The most commonly reported adverse events were transient facial flushing and injection-site pain [1].
The population the evidence came from, and the one being sold to
Growing children with a diagnosed pituitary deficiency are not the customers of a peptide subscription. So the useful question is what has been published on sermorelin for the use it is actually marketed for — energy, body composition, recovery, aging in healthy adults.
We ran the census in September 2026. A PubMed search for sermorelin in the title or abstract alongside any of anti-aging, antiaging, longevity or healthy adults returns zero records. The control searches the same day rule out a blocked probe: sermorelin alone returns 332 records, and the molecule’s technical name, GHRH (1-29), returns 232. The literature on this peptide is substantial. None of it is about the reason it is being sold to you.
The same search run for the pairing sellers actually ship — sermorelin together with NAD⁺ in the title or abstract — also returns zero. The two are routinely bundled into one subscription and have never been studied together, in either direction, at any dose.
A 2026 review in a sports medicine journal reached the same place from the clinical side. Surveying the peptides marketed direct to patients — BPC-157, CJC-1295, ipamorelin, MOTS-C, thymosin beta-4, sermorelin and others — it found that many show favorable tissue repair and metabolic outcomes in animal models while rigorous human safety data are scarce, with potential for serious harm, and it discusses the placebo effect as a mediator of perceived peptide efficacy and the role social media plays in amplifying it [3].
NAD⁺ has the same shape of problem, in a different literature
It would be convenient to end with “so buy the NAD⁺ instead”. The census does not support that either. A PRISMA-guided systematic review published in early 2026 swept human and rodent intervention studies of NAD-related compounds from January 2010 to October 2025 and identified 113 eligible studies, 33 of them human intervention studies and 28 randomized. Oral precursors consistently demonstrated biochemical target engagement and were generally well tolerated, while effects on functional, metabolic and vascular outcomes were heterogeneous and often null. No eligible outcomes trial evaluated intravenous or intramuscular NAD⁺ at all [4].
So both products arrive at your door with a real mechanism, a real literature, and no controlled trial demonstrating the outcome on the landing page. The difference is where the gap sits. Sermorelin has outcome trials in the wrong population; injected NAD⁺ has none in any population.
What they genuinely have in common
A supply chain. Both reach American buyers as compounded preparations from a pharmacy the seller usually declines to name, which means they are not FDA-approved and are not reviewed by the FDA for safety, efficacy or quality before they are dispensed. Both are billed as recurring subscriptions. And both are frequently sold without a milligram figure anywhere on the page, which makes a price impossible to compare against a competitor’s — the single most useful thing to check before you buy either. The sellers on our injection board that do publish a dose are flagged for exactly that reason, and the cheapest NAD⁺ therapy board ranks on what a stated quantity actually costs.
If you are choosing between them
You are not, really — they do unrelated things, so the honest answer is that the question has no winner. What you can decide is whether either purchase is supported well enough to make.
For sermorelin, the thing to establish before spending is whether anybody has measured your growth hormone status, because the entire human evidence base for treating with it is in people with a diagnosed deficiency. For NAD⁺, the format with randomized human trials behind its biomarker claim is the oral precursor, not the injection sitting next to the sermorelin on the same order form. And if a seller has filed NAD⁺ under “peptide therapy” on that form, you have learned something about how carefully the rest of the page was written.